Although the prevalence of steatosis is similar in hepatitis B virus-hepatitis C virus (HBV-HCV) coinfected patients compared to HCV individuals, there may be an inhibitory effect of HCV‐induced steatogenesis by HBV in certain subgroups of patients, a recent study suggests. The multicenter analysis examined the influence of coinfection with HBV on prevalence of steatosis in chronic hepatitis C in a multicenter cohort of HBV-HCV subjects. Steatosis prevalence and severity was assessed in a cohort of HBV-HCV coinfected subjects compared the HCV and HBV monoinfected controls. Among the details:

• 85 HBV-HCV, 69 HBV, and 112 HCV individuals were included.
• There was no significance difference in steatosis prevalence between HBV-HCV and the HCV groups (33% vs 45%).
• In subgroup analysis, lean HBV‐HCV subjects with detectable HBV DNA had less steatosis than lean HCV subjects matched for HCV viremia (15% vs 45%).
• Overall, prevalence of steatosis > 5% was similar in HBV‐HCV infection compared to HCV (pooled odds ratio [OR] 0.91) although there was significant heterogeneity.